OsteoCentric Technologies
- Industry
- Medical Devices
- Founded Year
- 2015
- Headquarters
- Austin, Texas, United States
- Employee Count
- 80
Key People
- Eric W. Brown - Founder and Chief Executive Officer
- Jason E. Topolosky - Chief Business Officer
- RJ Brideau - Chief Operating Officer
- Jim Ford - Chief Financial Officer
- Andrew Fauth - Chief Technology Officer
- Gavin Sontag - President & General Manager OsteoCentric Spine, LLC
- Mike Saunders - President & General Manager OsteoCentric Trauma, LLC
- Todd Evans - Vice President of Quality and Regulatory Affairs
- Stewart Withrow - Vice President & General Manager OsteoCentric SI Fusion, LLC
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The executive team comprises seasoned professionals with extensive experience in the medical device industry.
The leadership team includes individuals with over two decades of experience in medical devices, holding significant positions in renowned companies. Their collective expertise positions OsteoCentric Technologies favorably in the market.
- Clinical Need
-
Aspect: Very Strong
Summary: The company's UnifiMI technology addresses critical issues of implant instability and bone preservation in orthopedic procedures.
UnifiMI offers a less invasive method to secure implants, preserving bone integrity and providing immediate stability. This innovation directly addresses challenges in orthopedic surgeries, enhancing patient outcomes.
- Competition
-
Aspect: Somewhat crowded
Summary: The orthopedic device market is competitive, with several established players.
The orthopedic sector features numerous companies offering implant solutions. However, OsteoCentric's focus on mechanical integration and bone preservation provides a unique value proposition that can distinguish it from competitors.
- Technical Challenge
-
Aspect: Predictable
Summary: The development of UnifiMI technology involves manageable technical challenges.
With a dedicated innovation center and a team experienced in medical device development, OsteoCentric is equipped to handle the technical aspects of product development and refinement.
- Patent
-
Aspect: Very Strong
Summary: The company holds over 70 patents globally, indicating a robust intellectual property portfolio.
The extensive number of patents underscores the company's commitment to innovation and provides a barrier to entry for potential competitors, securing its market position.
- Financing
-
Aspect: Well-funded
Summary: The company has secured significant funding, including a $30 million investment led by Squadron Capital and OnPoint Advisors.
The substantial investment enables the company to accelerate product launches, expand into new market segments, and invest in research and development, fostering growth and innovation.
- Regulatory
-
Aspect: 510k/PMA
Summary: The company has achieved over 20 FDA clearances, facilitating market entry.
Obtaining multiple FDA clearances demonstrates the company's adherence to regulatory standards, enabling it to market its products confidently and expand its customer base.
Opportunity Rollup
- Odds of Success
- 3.8
- Peak Market Share
- 4.85
- Segment CAGR
- 3.0%
- Market Segment
- Orthopedic Devices
- Market Sub Segment
- Implantable Fixation Devices
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.24 |
| 2 | 0.73 |
| 3 | 1.70 |
| 4 | 3.40 |
| 5 | 4.85 |
Key Takeaway
OsteoCentric Technologies, with its innovative UnifiMI technology and experienced leadership, is well-positioned to address critical needs in the orthopedic implant market, despite facing a competitive landscape.